Invest in a mission that saves lives
Gencovery opens its capital to individual investors from €50. Join a unique human, scientific and financial adventure — and benefit from a x10 to x50 growth potential.
Mission-driven company since 9 May 2026
Transform and improve lives through a secure, open, ethical and collaborative model.
Choose your investment amount
Request subject to approval · No commitment at this stage
Where does the raise stand?
Phase 1 figures, updated with every finalised investment.
Why we are raising funds
Discover how Gencovery democratises access to data and AI for the well-being of all.
Why invest in Gencovery?
Save lives at global scale
Your investment funds technology that accelerates medical research, improves diagnostics and democratises access to care in Africa and worldwide.
x10 to x50 return potential
Invest in Phase 1 at a €5M valuation and benefit from growth potential towards €50M and beyond. A 3-year horizon for significant returns.
BSA-AIR + 20% conversion bonus
Phase 1 structured via BSA-AIR (SAFE bonds). At conversion, you get a 20% bonus vs future investors — a structural advantage for early backers.
Unique & patentable technology
Constellab is the most advanced data and AI infrastructure for life sciences. 5+ years of R&D, €1M+ invested, 10+ active clients.
Measurable impact from the first euro
Every euro invested contributes directly: 3¢ to Les Ponts de Mariane foundation, 3¢ to high-impact health projects, 6¢ to commercial development, R&D and the Constellab platform.
A leading scientific ecosystem
Partners: Institut Imagine / Necker Hospital, pharmaceutical CROs, African health institutions. A community of experts in service of open innovation.
Where does every euro you invest go?
Gencovery commits to allocating your investment in a transparent and traceable manner.
Les Ponts de Mariane Foundation
Funds the building of digital bridges to connect and save lives in the most fragile regions of the world.
High-impact health projects
Funding concrete projects: digital twin with Institut Imagine / Necker Hospital, digitising African health networks with Constellab Care.
Commercial growth, R&D & platform
Fund commercial development, accelerate R&D and develop the Constellab platform with its AI modules and global data exchange network.
Mission-driven company since 9 May 2026
Transform and improve lives through a secure, open, ethical and collaborative model.
As a mission-driven company, Gencovery enshrines these commitments in its bylaws. Your interests as an investor are aligned with those of the company and the ultimate beneficiaries.
3 phases to change the world
We raise funds in three stages to execute our vision in a disciplined, measurable and impactful way.
1 000 000 €
Target · September 2027
Milestones
Execution of CROPulse: establishing leadership on the Pharma value chain. Deploying Constellab to partner CROs and structuring the commercial network.
10 000 000 €
Target · September 2028
Milestones
Deployment of the Constellab marketplace: global scientific data exchange network.
€1M · Institut Imagine / Necker Hospital: build and validate a digital twin of cellular metabolism to accelerate rare disease diagnosis in children from genomics and transcriptomics data.
€1M · Constellab Care: digitise health networks in Africa (hospitals, populations) for equitable access to care.
€1M · Les Ponts de Mariane Foundation, founded by Djomnagan Adama Ouattara — funding digital bridges that save lives.
100 000 000 €
Target · September 2030
Milestones
Global deployment of Constellab Edge: making data sovereignty and AI accessible to every scientific organisation on the planet.
Global democratisation of Constellab Care and connected Constellab applications for universal healthcare.
€10M invested in the Les Ponts de Mariane foundation to build digital bridges connecting isolated communities to health data, education and economic life.
Phase 1 investor opportunity
Investing in Phase 1 means benefiting from an entry valuation of €5M, a 20% BSA-AIR bonus at conversion, and a x10 to x50 value multiplication potential over 3 years. It is also the promise of contributing to saving lives worldwide through Gencovery technology and the Les Ponts de Mariane foundation.
4× faster medical diagnosis
In partnership with Institut Imagine and Necker Hospital, Gencovery uses Constellab to build a digital twin of cellular metabolism. By cross-referencing genomics and transcriptomics data, this model multiplies by 4 the speed of rare disease diagnosis in children — demonstrating the concrete impact of your investment on real lives.
Everything you need to know before you start
Do you still have a question?
Our team is at your disposal to answer them.
What is the minimum amount to invest in Gencovery?
You can invest from as little as €50. Our goal is to make investment accessible to the widest possible audience, whether it's an initial discovery commitment or more significant support. Symbolic tiers are available: €50 (Explorer), €100 (Engaged), €500 (Actor), €1,000 (Pioneer), plus a free-amount option for anything beyond.
What is BSA-AIR and how does it work?
BSA-AIR (Bon de Souscription d'Actions — Accord d'Investissement Rapide) is the French equivalent of the American SAFE bond. It is a simple financial instrument that lets you invest now and receive shares at a future funding round, without needing to negotiate a complex valuation today. In Phase 1, investors benefit from a 20% bonus at conversion compared to the next round's investors — rewarding the trust placed upfront.
What is Gencovery's valuation and what is the return potential?
Phase 1 opens at an initial valuation of €5M. The goal is to reach a valuation of €50M by 2027-2028, representing a x10 potential. Beyond that, Phase 3 aims to raise €100M by 2030 for global deployment, with a x50 potential for early investors. These projections are based on execution of the CROPulse roadmap and Constellab's commercial growth.
Investing carries risks. Projections are not guaranteed.
What are the risks associated with this investment?
Like any investment in a growing company, this carries risks: risk of partial or total capital loss, liquidity risk (shares are not publicly traded), and execution risk related to the roadmap. To mitigate these risks, Gencovery already has 5+ years of existence, €1M+ R&D invested, 10+ active clients and a mature product. We recommend only investing amounts you can afford to lock up over a 3-to-5 year horizon.
When and how will I get my investment back?
Exit can occur at a liquidity event: an IPO or secondary sale of your securities to another investor. The target horizon is 3 to 5 years from your investment date. BSA-AIRs convert to shares at the next funding round, after which your shareholder rights are fully established. No cash repayment is guaranteed before such an event.
Where exactly does the money I invest go?
Every euro invested in Gencovery is allocated transparently: 3 cents go to the Les Ponts de Mariane foundation to build life-saving digital bridges, 3 cents fund high-impact health projects (digital twin, Constellab Care in Africa), and 6 cents are invested in commercial development, R&D and the Constellab platform. This allocation reflects our mission-driven company status, enshrined in our bylaws since 9 May 2026.
What is a mission-driven company and why does it matter?
A mission-driven company is one that enshrines social or environmental impact objectives in its legal bylaws, alongside financial goals. Since 9 May 2026, Gencovery is officially a mission-driven company with the purpose: "Transform and improve lives through a secure, open, ethical and collaborative model." This means every strategic decision — including the use of your investment — is legally bound to uphold this commitment, under the oversight of an independent mission committee.
What is Constellab and why is it a competitive advantage?
Constellab is the data and AI platform developed by Gencovery for life sciences. It allows scientific organisations to manage, analyse and share complex data in a sovereign, secure and reproducible way — without dependency on American clouds. After 5+ years of R&D, Constellab is a mature technology used by CROs, pharmaceutical labs and academic institutions. It is the main asset underpinning Gencovery's value and the core of our growth roadmap.
What is the Les Ponts de Mariane foundation?
The Les Ponts de Mariane foundation, created by Djomnagan Adama Ouattara (co-founder of Gencovery), has a mission to build digital bridges to connect and improve the lives of the most vulnerable populations in the world. It funds concrete digital infrastructure projects — access to health data, education and economic life — in isolated regions, primarily in Africa. 3 cents of every euro invested in Gencovery are directly allocated to this foundation. Learn more at lespontsdemariane.org.
How do I invest in practice — credit card or bank transfer?
Two subscription methods are available: by credit card (fast, immediate processing) or by bank transfer (suitable for larger amounts). In both cases, you will receive an electronically signed BSA-AIR subscription agreement and an investment summary. For any questions about the process, do not hesitate to contact us directly — our team is available to guide you.